AbbVie (ABBV) said Friday it received approval from the US Food and Drug Administration for its antibiotic Emblaveo for the treatment of adults with complicated intra-abdominal infections.
The approval covers Emblaveo's use with metronidazole in patients who have limited or no alternative options to treat their infections, including those caused by Gram-negative bacteria which can become antimicrobial resistant, the drugmaker said.
Emblaveo will be available for commercial use in Q3, AbbVie said.
Price: 191.52, Change: -1.45, Percent Change: -0.75
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。